SVRA
What one share of Savara holds
Pharmaceutical Preparations
Savara Inc. (together with its subsidiaries “Savara,” the “Company,” “we,” “our” or “us”) is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our sole program, molgramostim inhalation solution ("MOLBREEVI" or "molgramostim"), is an investigational inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor ("GM-CSF") in Phase 3 development for autoimmune pulmonary alveolar proteinosis (“autoimmune PAP”).
Savara’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.58 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.46 |
| Cash and investments | $0.20 |
| Debt | $0.15 |
| Book value | $0.70 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.20 | −$5.62 | $0.00 | −$4.27 | — | −$11.34 |
| 2017 | $0.00 | −$1.76 | $0.03 | −$1.64 | — | $3.91 |
| 2018 | — | −$1.85 | $0.00 | −$1.18 | — | $3.08 |
| 2019 | $0.00 | −$1.95 | $0.00 | −$1.13 | — | $2.00 |
| 2020 | $0.00 | −$0.84 | $0.00 | −$0.67 | — | $1.19 |
| 2021 | — | −$0.32 | $0.00 | −$0.30 | — | $1.27 |
| 2022 | — | −$0.25 | $0.00 | −$0.23 | — | $0.94 |
| 2023 | — | −$0.33 | $0.00 | −$0.31 | — | $1.02 |
| 2024 | — | −$0.48 | $0.00 | −$0.45 | — | $0.99 |
| 2025 | — | −$0.53 | $0.00 | −$0.45 | — | $0.99 |